Search
elotuzumab (Empliciti)
Indications:
- relapsed or refractory multiple myeloma
- used in combination with lenalidomide & dexamethasone [1]
Dosage:
400 MG Injection [Empliciti]
Adverse effects:
- lymphocytopenia
- neutropenia
- fatigue,
- pneumonia
- infusion reactions
Mechanism of action:
- immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7) [1]
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- Lonial S, Dimopoulos M, Palumbo A et al
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
N Engl J Med. 2015 Aug 13;373(7):621-31..
PMID: 26035255